Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is a promising company with positive catalysts expected in the near future, including key regulatory meetings, potential accelerated approval decisions, and monetization of the PRV. The company has a strong pipeline of product candidates and a clear focus on addressing the need for new treatments in osteosarcoma and other solid tumors. The financials show a heavier cost structure due to development and regulatory work, but the company has already secured funding and is well-positioned to meet regulatory milestones. Overall, OS Therapies has a positive outlook due to its promising product pipeline, strong regulatory momentum, and potential for market entry in the second half of 2026.

Bears say

OS Therapies is currently in the clinical stage, with highly ambitious goals and only two drug technologies in preclinical development, leading to high levels of clinical/regulatory and partnership/financial risk for investors. Additionally, the company's focus on a niche market, osteosarcoma, poses a potential commercial risk and the company may face legal and intellectual property risks as they move towards market approval. With a limited pipeline and smaller target market compared to other pharmaceutical companies, OS Therapies may struggle to gain significant market share, leading to potential financial concerns for investors.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.